This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Acute Bronchiolitis and Severity Markers: Interest in Protein CC16 (CC16)

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by University Hospital, Clermont-Ferrand
Sponsor:
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT02984046
First received: November 28, 2016
Last updated: December 2, 2016
Last verified: December 2016
  Purpose

Acute bronchiolitis is a common viral infection in infants mainly due to RSV and rhinovirus.

Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of epithelial aggression. Its rate increase during RSV bronchiolitis in infants less than 7 months. It could be an early predictive biomarker of the severity of acute bronchiolitis, and secondarily for the development of asthma.

Two other markers of airway aggression seem to increase during acute bronchiolitis: serum SP-D protein and serum soluble receptor sRAGE.


Condition Intervention
Acute Bronchiolitis Drug: Protein CC16

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Acute Bronchiolitis and Severity Markers: Interest in Protein CC16

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Serum CC16 rate [ Time Frame: at day 1 ]

Secondary Outcome Measures:
  • Urinary CC16 rate [ Time Frame: at day 1 ]
  • SP-D rates [ Time Frame: at day 1 ]
  • sRAGE rates [ Time Frame: at day 1 ]

Estimated Enrollment: 200
Study Start Date: November 2015
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: acute bronchiolitis
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
Drug: Protein CC16

Detailed Description:
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system established at the time of the admission in Paediatric Emergency Unit. Secondary end-points: correlation with urinary CC16; correlation with risk factors for bronchial epithelial aggression, viruses, immediate morbidity and mortality. Study of serum SP-D and sRAGE levels.
  Eligibility

Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Infants under 1 year old hospitalized for acute bronchiolitis

Exclusion Criteria:

  • Broncho dysplasia
  • Preterm under 34 weeks
  • Cystic fibrosis
  • Immune deficiency
  • Suspicion of primary ciliary dyskinesia
  • Congenital heart disease
  • Acute renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02984046

Contacts
Contact: Patrick LACARIN 0473751195 placarin@chu-clermontferrand.fr

Locations
France
CHU Clermont-Ferrand Recruiting
Clermont-Ferrand, France, 63003
Contact: Patrick LACARIN    0473751195    placarin@chu-clermontferrand.fr   
Principal Investigator: André LABBE         
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: André LABBE University Hospital, Clermont-Ferrand
  More Information

Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT02984046     History of Changes
Other Study ID Numbers: CHU-0294
2015-A01587-42 ( Other Identifier: 2015-A01587-42 )
Study First Received: November 28, 2016
Last Updated: December 2, 2016

Keywords provided by University Hospital, Clermont-Ferrand:
Acute bronchiolitis
RSV
CC16
SP-D
sRAGE
Severity
Biomarkers

Additional relevant MeSH terms:
Bronchiolitis
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on August 22, 2017